NLS Nautilus Inc

Nautilus, Inc. Reports Results for the First Quarter 2018

Nautilus, Inc. (NYSE: NLS) today reported its unaudited operating results for the first three months ended March 31, 2018.

Q1 2018 Highlights

All comparisons relate to the first quarter of 2017 unless otherwise indicated:

  • Revenues:
    • Total revenue increased 1.4% to $114.8 million compared to prior year of $113.3 million and guidance range of $110.0 to $113.0 million.
    • Direct segment sales decreased 4.7% to $71.2 million primarily from the expected decline in TreadClimber® sales, partially offset by growth of new products, including the Bowflex HVT® product.
    • Retail segment sales increased 13.7% to $43.0 million, reflecting strong growth across a variety of product lines, as well as growth in specialty and commercial customers.
  • Gross Margins:
    • Total company gross margins decreased by 320 basis points to 51.3% primarily due to a reduction in Direct gross margins, coupled with a shift in segment revenue mix from Direct to Retail.
    • Direct margins decreased by 250 basis points due to a shift in product mix to lower margin HVT® products and treadmills.
    • Retail margins decreased by 80 basis points due to increased product costs.
  • Operating income decreased 15.7% to $10.7 million compared to prior year of $12.7 million due to the decline in gross margin and added investments in key strategic initiatives.
  • Income from continuing operations for the first quarter of 2018 was $8.1 million, or $0.27 per diluted share, compared to income from continuing operations of $8.2 million, or $0.26 per diluted share in the prior year quarter.
  • EBITDA from continuing operations decreased 11.8% to $13.1 million compared to $14.9 million in the prior year period.
  • At March 31, 2018, cash and marketable securities increased to $92.7 million and debt decreased to $44.0 million, compared to $85.2 million and $48.0 million, respectively, at December 31, 2017.
  • Repurchased $2.7 million of stock in the open market as part of previously announced stock repurchase program.

Bruce M. Cazenave, Chief Executive Officer, stated, “First quarter 2018 revenue and operating income exceeded the guidance range we provided and were driven by solid momentum in our Retail segment. The Retail segment achieved 14% growth in the first quarter as we experienced broad based sales growth across existing and recently introduced products with several key partners and improved performance in the specialty retail channel. As anticipated, we experienced a decline in the Direct segment revenues due to the phase-down of the mature TreadClimber® product line but are well positioned to return to growth in this segment beginning the third quarter of 2018. New products introduced during the middle of last year such as the Bowflex Results Series™ and HVT® products continued to meaningfully contribute during the first quarter, and we are on track to launch additional Direct and Retail segment products later this year. The introduction of the Commercial Max Trainer® product at the recent IHRSA show has been extremely well received, and we look forward to the anticipated uplift in Octane sales when the product starts shipping during the third quarter of this year.”

Mr. Cazenave continued, “Implementation of the multi-faceted 2018 plan we described in previous communications is proceeding as planned and on schedule. This includes systems integration, consolidation of warehousing facilities, supply base realignment and restructuring of our international sales and support teams. Progress in developing our new digital technology platform is also advancing as planned. These initiatives are anticipated to enhance and support our growth initiatives, including new product introductions and improved margins, going forward. Based on our first quarter results, planned rollout of new offerings and operational improvements, we are well positioned to return to full year top line growth in 2018, and reaffirm our full year guidance range on revenue and operating income.”

For further information, see “Results of Operations Information” attached hereto.

Segment Results

Net sales for the Direct segment were $71.2 million in the first quarter of 2018, a decrease of 4.7% over the comparable period last year as the expected decline in TreadClimber® sales, coupled with a decline in Max Trainer® sales, was partially offset by the growth of new products, including the Bowflex Results Series™ treadmills and ellipticals. Operating income for the Direct segment was $11.3 million for the first quarter of 2018, compared to $15.3 million in the first quarter of last year. Operating income was negatively impacted by the decline in gross margins and lower media returns, partially offset by a decrease in consumer financing fees. Gross margin for the Direct segment declined by 250 basis points resulting from a shift in product mix to lower margin HVT® products and treadmills.

Net sales for the Retail segment were $43.0 million in the first quarter of 2018, an increase of 13.7% when compared to $37.8 million in the first quarter last year. The increase reflected robust growth across a variety of product lines and sales growth with specialty and commercial customers. Operating income for the Retail segment was $3.9 million for the first quarter of 2018 compared to $2.2 million in the first quarter of last year. The increase in Retail segment operating income was primarily due to the higher net sales, coupled with the non-recurrence of a $1.2 million reserve recorded in the same period of the prior year. Retail segment gross margin was 31.2% in the first quarter of 2018, compared to 32.0% in the same quarter of the prior year, reflecting increased product costs due to unfavorable changes in foreign currency exchange rates.

Royalty revenue in the first quarter 2018 was $0.6 million, compared to $0.7 million for the same quarter of last year. The reduction in royalty revenue reflects the renegotiation of a certain license.

For further information, see “Segment Information” attached hereto.

Balance Sheet

As of March 31, 2018, the Company had cash and marketable securities of $92.7 million and debt of $44.0 million, compared to cash and marketable securities of $85.2 million and debt of $48.0 million at year end 2017. During the first quarter, the Company purchased $2.7 million of stock in the open market as part of its previously announced stock repurchase program. Working capital of $93.6 million as of March 31, 2018 was $2.4 million higher than the 2017 year-end balance of $91.1 million. Inventory as of March 31, 2018 was $37.7 million, compared to $53.4 million as of December 31, 2017 and $34.3 million at the end of the first quarter last year.

For further information, see “Balance Sheet Information” attached hereto.

Conference Call

Nautilus will host a conference call to discuss the Company’s operating results for the first quarter ended March 31, 2018 at 4:30 p.m. ET (1:30 p.m. PT) on Monday, May 7, 2018. The call will be broadcast live over the Internet hosted at http://www.nautilusinc.com/events and will be archived online within one hour after completion of the call. In addition, listeners may call (888) 394-8218 in North America and international listeners may call (323) 701-0225. Participants from the Company will include Bruce M. Cazenave, Chief Executive Officer, Sid Nayar, Chief Financial Officer, and William B. McMahon, Chief Operating Officer.

A telephonic playback will be available from 7:30 p.m. ET, May 7, 2018, through 11:59 p.m. ET, May 21, 2018. Participants can dial (844) 512-2921 in North America and international participants can dial (412) 317-6671 to hear the playback. The passcode for the playback is 2770686.

Non-GAAP Presentation

In addition to disclosing results determined in accordance with GAAP, Nautilus has presented EBITDA from continuing operations, a non-GAAP financial measure, for the three months ended March 31, 2018 and 2017.

The Company defines EBITDA from continuing operations as its income from continuing operations, adjusted to exclude interest expense (income), income tax expense of continuing operations, and depreciation and amortization expense. The Company uses EBITDA from continuing operations in evaluating its operating results and for financial and operational decision-making purposes such as budgeting and establishing operational goals. The Company believes that EBITDA from continuing operations helps identify underlying trends in its business that could otherwise be masked by the effect of the items that are excluded from EBITDA from continuing operations and enhances the overall understanding of the Company’s past performance and future prospects. The Company presents EBITDA from continuing operations as a complement to results provided in accordance with GAAP, and these results should not be regarded as a substitute for GAAP. The Company strongly encourages you to review all of its financial statements and publicly-filed reports in their entirety and to not rely on any single financial measure.

For a quantitative reconciliation of our non-GAAP financial measures to the most comparable GAAP measures, see "Reconciliation of Non-GAAP Financial Measures" included with this release.

About Nautilus, Inc.

Headquartered in Vancouver, Washington, Nautilus, Inc. (NYSE: NLS) is a global fitness solutions company that believes everyone deserves a fit and healthy life. With a brand portfolio including Bowflex®, Nautilus®, Octane Fitness®, Schwinn® and Universal®, Nautilus, Inc. develops innovative products to support healthy living through direct and retail channels, as well as in commercial channels with Octane Fitness® products. Nautilus, Inc. uses the investor relations page of its website (www.nautilusinc.com/investors) to make information available to its investors and the market.

This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including: projected or forecasted financial and operating results; statements regarding the Company's prospects, resources or capabilities; current or future financial and economic trends; planned investments, restructurings and similar initiatives and the anticipated or targeted results therefrom; future plans for introduction of new products; and anticipated demand for the Company's new and existing products. Factors that could cause Nautilus, Inc.’s actual results to differ materially from these forward-looking statements include: our ability to timely acquire inventory that meets our quality control standards from sole source foreign manufacturers at acceptable costs; an inability to pass along or otherwise mitigate the impact of raw material price increases and other cost pressures; experiencing delays and/or greater than anticipated costs in connection with launch of new products, entry into new markets, or restructuring initiatives; changes in consumer fitness trends; changes in the media consumption habits of our target consumers or the effectiveness of our media advertising; a decline in consumer spending due to unfavorable economic conditions; and softness in the retail marketplace. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the “Risk Factors” set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events or circumstances.

RESULTS OF OPERATIONS INFORMATION

The following summary contains information from our condensed consolidated statements of operations for the three months ended March 31, 2018 and 2017 (unaudited and in thousands, except per share amounts):

   

Three Months Ended

March 31,

2018   2017
 
Net sales $ 114,813 $ 113,252
Cost of sales 55,942   51,507  
Gross profit 58,871 61,745
 
Operating expenses:
Selling and marketing 36,763 37,665
General and administrative 6,910 7,486
Research and development 4,501   3,911  
Total operating expenses 48,174 49,062
 
Operating income 10,697 12,683
Other expense, net (34 ) (360 )
Income from continuing operations before income taxes 10,663 12,323
Income tax expense 2,523   4,138  
Income from continuing operations 8,140 8,185
Loss from discontinued operations(1) (81 ) (1,092 )
Net income $ 8,059   $ 7,093  
 
Basic income per share from continuing operations $ 0.27 $ 0.27
Basic loss per share from discontinued operations   (0.04 )
Basic net income per share $ 0.27   $ 0.23  
 
Diluted income per share from continuing operations $ 0.27 $ 0.26
Diluted loss per share from discontinued operations   (0.04 )
Diluted net income per share(2) $ 0.26   $ 0.23  
 
Shares used in per share calculations:
Basic 30,314 30,713
Diluted 30,591 31,127
 
Select Metrics:
Gross margin 51.3 % 54.5 %
Selling and marketing % of net sales 32.0 % 33.3 %
General and administrative % of net sales 6.0 % 6.6 %
Research and development % of net sales 3.9 % 3.5 %
Operating income % of net sales 9.3 % 11.2 %
 

(1) The three months ended March 31, 2017 include a $1.2 million expense related to a lawsuit settlement with Biosig Instruments, Inc.

(2) May not add due to rounding.

SEGMENT INFORMATION

The following table presents certain comparative information by segment for the three months ended March 31, 2018 and 2017 (unaudited and in thousands):

   

Three Months Ended

March 31,

  Change
2018   2017 $   %
Net sales:
Direct $ 71,201 $ 74,703 $ (3,502 ) (4.7 )%
Retail 42,993 37,805 5,188 13.7 %
Royalty 619   744   (125 ) (16.8 )%
$ 114,813   $ 113,252   $ 1,561   1.4 %
 
Operating income (loss):
Direct $ 11,291 $ 15,333 $ (4,042 ) (26.4 )%
Retail 3,921 2,212 1,709 77.3 %
Unallocated corporate (4,515 ) (4,862 ) 347   7.1 %
$ 10,697   $ 12,683   $ (1,986 ) (15.7 )%

BALANCE SHEET INFORMATION

The following summary contains information from our condensed consolidated balance sheets as of March 31, 2018 and December 31, 2017 (unaudited and in thousands):

   
As of
March 31, 2018   December 31, 2017
Assets
 
Cash and cash equivalents $ 23,747 $ 27,893
Available-for-sale securities 68,905 57,303
Trade receivables, net of allowances of $133 and $119 29,796 42,685
Inventories 37,699 53,354
Prepaids and other current assets 7,132 7,240
Income taxes receivable 30   17
Total current assets 167,309 188,492
 
Property, plant and equipment, net 16,591 15,827
Goodwill 61,963 62,030
Other intangible assets, net 56,933 57,743
Deferred income tax assets, non-current 287
Other assets 704   684
Total assets $ 303,787   $ 324,776
 
Liabilities and Shareholders' Equity
 
Trade payables $ 41,724 $ 66,899
Accrued liabilities 12,126 10,764
Warranty obligations, current portion 3,900 3,718
Note payable, current portion 15,993   15,993
Total current liabilities 73,743 97,374
 
Warranty obligations, non-current 2,158 2,399
Income taxes payable, non-current 3,103 2,955
Deferred income tax liabilities, non-current 9,687 8,558
Other non-current liabilities 2,208 2,315
Note payable, non-current 27,988 31,986
Shareholders' equity 184,900   179,189
Total liabilities and shareholders' equity $ 303,787   $ 324,776
 

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

The following table presents a reconciliation of EBITDA from continuing operations for the three months ended March 31, 2018 and 2017 (unaudited and in thousands):

   

Three Months Ended

March 31,

2018   2017
 
Income from continuing operations $ 8,140 $ 8,185
Interest expense, net 21 313
Income tax expense of continuing operations 2,523 4,138
Depreciation and amortization 2,439   2,244
Earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations $ 13,123   $ 14,880
 

EN
07/05/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nautilus Inc

MarketLine Department
  • MarketLine Department

iFIT Health & Fitness Inc - Strategy, SWOT and Corporate Finance Repor...

Summary iFIT Health & Fitness Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights iFIT Health & Fitness Inc (iFIT) is a fitness equipment manufacturer. The company’s product portfolio includes treadmills, incline trainers, elliptical machines, stationary bikes, ho...

Nautilus Inc: 1 director

A director at Nautilus Inc bought 20,000 shares at 2.150USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

W WAYFAIR INC.
DHR DANAHER CORPORATION
VEEV VEEVA SYSTEMS INC CLASS A
USNA USANA HEALTH SCIENCES INC.
TSCO TRACTOR SUPPLY COMPANY
TBPH THERAVANCE BIOPHARMA INC
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SLP SIMULATIONS PLUS
SLGN SILGAN HOLDINGS INC.
SFM SPROUTS FARMERS MARKETS INC.
RRC RANGE RESOURCES CORPORATION
RGEN REPLIGEN CORPORATION
RARE ULTRAGENYX PHARMACEUTICAL INC.
PYPL PAYPAL HOLDINGS INC
OLLI OLLIE'S BARGAIN OUTLET HOLDINGS INC
NLS NAUTILUS INC
NGVC NATURAL GROCERS BY VITAMIN COTTAGE INC
MTRN MATERION CORPORATION
MSCI MSCI INC. CLASS A
MOH MOLINA HEALTHCARE INC.
MMSI MERIT MEDICAL SYSTEMS INC.
MKTX MARKETAXESS HOLDINGS INC.
LMNX LUMINEX CORP
LDOS LEIDOS HOLDINGS INC.
INO INOVIO PHARMACEUTICALS INC.
HALO HALOZYME THERAPEUTICS INC.
HAE HAEMONETICS CORPORATION
GFI GOLD FIELDS LTD. ADS
GBT GLOBAL BLOOD THERAPEUTICS INC
FOLD AMICUS THERAPEUTICS INC.
EBS EMERGENT BIOSOLUTIONS INC.
CONE CYRUSONE INC.
CNC CENTENE CORPORATION
CIEN CIENA CORPORATION
CERS CERUS CORP.
CALX CALIX NETWORKS
BMRN BIOMARIN PHARMACEUTICAL INC.
AU ANGLOGOLD ASHANTI LTD. ADS
ASC ARDMORE SHIPPING
ALXN ALEXION PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
ALLT ALLOT LTD
AGI. ALAMOS GOLD INC.
AAWW ATLAS AIR WORLDWIDE HOLDINGS INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
IRBT IROBOT CORPORATION
CCO. CAMECO CORPORATION
AEM. AGNICO EAGLE MINES LIMITED
NAT NORDIC AMERICAN TANKERS LIMITED
ENTG ENTEGRIS INC.
KLAC KLA CORPORATION
WERN WERNER ENTERPRISES INC.
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
WMK WEIS MARKETS INC.
FIZZ NATIONAL BEVERAGE CORP.
INSG INSEEGO CORP
PHI PHILIPPINE LONG DISTANCE TELEPHONE COMPANY ADS
OKTA OKTA INC. CLASS A
ARNA ARENA PHARMACEUTICALS INC.
QTRX QUANTERIX CORPORATION
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
SWCH SWITCH
VICR VICOR CORP.
ALLO ALLOGENE THERAPEUTICS
TBIO TRANSLATE BIO
MR MONTAGE RESOURCES CORP.
BYND BEYOND MEAT
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
CLVT CLARIVATE PLC (A)
ATEX ANTERIX INC
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
SQNS SEQUANS COMMUNICATIONS ADR
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

RGLD ROYAL GOLD INC
VRSN VERISIGN INC.
VNET 21VIANET GROUP INC. SPONSORED ADR CLASS A
TBPH THERAVANCE BIOPHARMA INC
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SLP SIMULATIONS PLUS
SLGN SILGAN HOLDINGS INC.
SFM SPROUTS FARMERS MARKETS INC.
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVDA NVIDIA CORPORATION
NLS NAUTILUS INC
MOH MOLINA HEALTHCARE INC.
LMNX LUMINEX CORP
JNJ JOHNSON & JOHNSON
IMMU IMMUNOMEDICS INC.
HALO HALOZYME THERAPEUTICS INC.
GFI GOLD FIELDS LTD. ADS
FOLD AMICUS THERAPEUTICS INC.
FAN FABRINET
FB FACEBOOK INC. CLASS A
EXEL EXELIXIS INC.
EBAY EBAY INC.
CTLT CATALENT INC
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CDNS CADENCE DESIGN SYSTEMS INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
AU ANGLOGOLD ASHANTI LTD. ADS
ALNY ALNYLAM PHARMACEUTICALS INC
AGI. ALAMOS GOLD INC.
ACAD ACADIA PHARMACEUTICALS INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
SW SIERRA WIRELESS INC.
IRBT IROBOT CORPORATION
CCO. CAMECO CORPORATION
AEM. AGNICO EAGLE MINES LIMITED
NAT NORDIC AMERICAN TANKERS LIMITED
CMG CHIPOTLE MEXICAN GRILL INC.
IONS IONIS PHARMACEUTICALS INC.
PETS PETMED EXPRESS INC.
UTHR UNITED THERAPEUTICS CORPORATION
INSG INSEEGO CORP
INSW INTERNATIONAL SEAWAYS INC.
NMI. KIRKLAND LAKE GOLD LTD.
SNAP SNAP INC. CLASS A
AKCA AKCEA THERAPEUTICS INC.
SSRM SSR MINING INC
ZLAB ZAI LAB LTD. SPONSORED ADR
QTRX QUANTERIX CORPORATION
CUE CUE BIOPHARMA INC
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
HEAR TURTLE BEACH CORP.
EVER EVERQUOTE
ARAV ARAVIVE
DOCU DOCUSIGN INC.
MR MONTAGE RESOURCES CORP.
DSSI DIAMOND S SHIPPING
SPNS SAPIENS INTERNATIONAL CORP. N.V.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
ARCT ARCTURUS THERAPEUTICS HOLDINGS INC
LVGO LIVONGO HEALTH
SQNS SEQUANS COMMUNICATIONS ADR
CGEN COMPUGEN LTD.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch